Oncology, neurology, and fatty liver disease are among the areas where one can expect to see significant activity this year, according to forecasts from investment bank analysts.
Anticipated highlights for 2020 include potentially the first regulatory approval of a drug to treat the liver disease nonalcoholic steatohepatitis, or NASH; the launches of two new drugs for sickle cell disease; and late-stage data for a drug to treat amyotrophic lateral sclerosis, among others. Several company executives also shared their insights in a story published over the weekend.
{iframe}https://medcitynews.com/2020/01/analysts-weigh-in-on-what-to-expect-in-biopharma-this-year/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=81624736&_hsenc=p2ANqtz-_uHDktNiTpoIb0DwR5ePPCpfhgj0xqB566IYoKAwCxe_y-Wa4Y7dTvJRtVjLx2si2MX-weg21sQYWhKksU8jeaPNua9w&_hsmi=81624736{/iframe}